Developer docs
API playgroundTry for free, no card

Search company profiles

United Immunity

Full company profile

uuid0003i6i

Namestring
United Immunity
Legal namestring
United Immunity Co., Ltd.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

United Immunity Co., Ltd. is a Japanese privately-held biotechnology company founded in November 2017 by Dr. Naozumi Harada and headquartered in Tokyo, with research operations at the Creative Lab for Innovation in Kobe (CLIK). The company develops and commercializes a proprietary drug delivery platform called the Myeloid Targeting Platform™, which consists of two nanoparticle formats built on pullulan polysaccharide chemistry: Pullulan Nanoparticle (PNP) for delivering small molecules, peptides, and proteins; and Pullulan-coated PEG-free Lipid Nanoparticle (P-LNP) for delivering nucleic acids including mRNA, siRNA, and DNA. Both formats selectively bind to the DC-SIGN (CD209) C-type lectin receptor expressed on macrophages and dendritic cells, enabling targeted delivery to tumor-associated macrophages (TAMs) and lymph node myeloid cells while avoiding the anti-PEG antibody issues associated with conventional lipid nanoparticles.

The company's pipeline targets cancer immunotherapy, infectious disease vaccines, and fibrosis applications, with lead candidates including UI-102 (TLR7/8 agonist in PNP for solid tumors, FDA IND cleared March 2026), UI-103 (in vivo CAR-Macrophages using P-LNP), and UI-201 (T-cell booster vaccine for TCR-T cell therapy in synovial sarcoma, Phase 1 completed). United Immunity has exclusively licensed foundational T-ignite® technology from Kyoto University and Mie University, and holds fundamental patents in Japan covering the Myeloid Targeting Platform and P-LNP compositions, with international filings underway.

The company operates a B2B platform licensing and co-development business model, generating revenue through technology licensing (upfront fees, milestones, royalties), research collaboration agreements with pharmaceutical partners (including AstraZeneca and Astellas/Xyphos), and non-dilutive government grants from Japanese agencies such as NEDO and AMED. As a pre-commercial biotech, United Immunity does not yet sell products and depends on partnership income and grant funding to advance its clinical pipeline. The company is supported by venture investors including Saisei Ventures, UTEC, Axil Capital, TOHO Holdings, and Rico Biomedical Startup Fund, and secured venture debt from Aozora Corporate Investment in March 2024.

Short descriptiontext

United Immunity is a Tokyo-based Japanese biotech developing the Myeloid Targeting Platform™, a pullulan-based nanoparticle drug delivery technology that selectively targets macrophages and dendritic cells via DC-SIGN receptor binding for cancer immunotherapy and vaccine applications, serving pharmaceutical partners through licensing and co-development agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, nanoparticle drug delivery, myeloid cell targeting, lipid nanoparticle platform, immuno-oncology platform
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy / Nanoparticle Drug Delivery
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

United Immunity licenses its Myeloid Targeting Platform technology, PNP, and P-LNP to pharmaceutical partners for use in their drug development programs. Licensing revenue derives from upfront payments, milestone payments, and royalties on approved products.

unitedimmunity.co.jp
2Co-Development and Research Collaborations
TypeProfessional Services
Description

The company enters joint research and co-development agreements with pharma companies (e.g., AstraZeneca, Astellas/Xyphos) where collaborative R&D generates funding through research fees, milestone payments, and future commercial royalties.

unitedimmunity.co.jp
3Government Grants
TypeSubscription Recurring
Description

United Immunity receives non-dilutive funding from Japanese government agencies including NEDO (Deep Tech/Startup support grant) and AMED (Strengthening Program for Pharmaceutical Startup Ecosystem; CiCLE grants), supporting preclinical and clinical development of pipeline programs.

unitedimmunity.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Myeloid Targeting Platform™
Description

Proprietary drug delivery platform using pullulan nanoparticles (PNP) and pullulan-coated lipid nanoparticles (P-LNP) for selective targeting of macrophages and dendritic cells via DC-SIGN receptor.

unitedimmunity.co.jp
Core offering1 text field

United Immunity develops and licenses the Myeloid Targeting Platform™, a proprietary nanoparticle drug delivery system comprising Pullulan Nanoparticle (PNP) and PEG-free Pullulan-coated Lipid Nanoparticle (P-LNP) that selectively deliver therapeutic payloads (small molecules, peptides, proteins, mRNA, siRNA, DNA) to macrophages and dendritic cells via DC-SIGN receptor binding. The company applies this platform to build an internal pipeline of immuno-oncology drug candidates (UI-102, UI-103, UI-201) and offers the technology to pharmaceutical partners through licensing, co-development, and research collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • UI-102 showed strong single-agent anti-tumor activity in multiple preclinical cold tumor models and clear synergy with checkpoint inhibitors in treatment-resistant tumor models
+2 more records
Product overview1 text field

United Immunity is a biotech company developing a proprietary Myeloid Targeting Platform™ consisting of two nanoparticle delivery systems: Pullulan Nanoparticle (PNP) for small molecules, peptides, and proteins, and Pullulan Lipid Nanoparticle (P-LNP) for nucleic acids (mRNA, siRNA, DNA). Both technologies selectively target macrophages and dendritic cells via DC-SIGN receptor binding. The company applies this platform to develop pipeline candidates including UI-102 (TLR7/8 agonist in PNP for solid tumors), UI-103 (in vivo CAR-Macrophages using P-LNP), and UI-201 (T-cell booster vaccine for TCR-T therapy). The platform enables drug delivery to tumor-associated macrophages and dendritic cells for cancer immunotherapy and vaccine applications.

Product and service6 records
1Myeloid Targeting Platform™
CategoryPlatform Technology / Drug Delivery
Description

A proprietary nanoparticle-based drug delivery platform technology that enables selective delivery of therapeutic agents to disease- and vaccination-associated macrophages and dendritic cells through specific binding of pullulan polysaccharide to the DC-SIGN receptor. The platform comprises two nanoparticle formats (PNP and P-LNP) supporting delivery of small molecules, peptides, proteins, and nucleic acids, and is licensed to and co-developed with pharmaceutical partners for cancer immunotherapy, infectious disease, autoimmune disease, fibrosis, and metabolic disease applications.

2Pullulan Nanoparticle (PNP)
CategoryNanoparticle Delivery Technology
Description

A nanoparticle consisting of cholesterol-modified pullulan polysaccharide formed by self-assembly through hydrophobic interaction. PNP encapsulates hydrophobic small molecules, peptides, and proteins and is administered via intravenous, subcutaneous, or intramuscular injection. It specifically targets DC-SIGN-expressing macrophages and dendritic cells for drug delivery and is non-antigenic, supporting multiple dosing.

3Pullulan Lipid Nanoparticle (P-LNP)
CategoryNanoparticle Delivery Technology
Description

A next-generation PEG-free lipid nanoparticle technology coated with pullulan polysaccharide, designed for delivery of mRNA, siRNA, and DNA to disease- and vaccination-associated myeloid cells. P-LNP avoids anti-PEG antibody-associated adverse effects and provides selectivity toward macrophages and dendritic cells via DC-SIGN binding.

4UI-102
CategoryDrug Candidate (Oncology)
Description

A PNP formulation encapsulating a TLR7/8 agonist for systemic injection targeting M2-like tumor-associated macrophages. UI-102 selectively accumulates in tumors where it repolarizes immunosuppressive M2-like TAMs into immunostimulatory M1-like TAMs, converting 'cold' tumors into 'hot' tumors. It is in Phase 1/2 development for solid tumors as monotherapy or in combination with checkpoint inhibitors, and received FDA IND clearance in March 2026.

5UI-103 (In Vivo CAR-Macrophages)
CategoryDrug Candidate (Cell Therapy / Oncology)
Description

An in vivo CAR-macrophage therapy program using P-LNP to deliver CAR mRNA directly to tumor-associated macrophages. The approach aims to generate CAR-M cells within the patient's body for off-the-shelf treatment of solid tumors with lower manufacturing costs and potential for repeat dosing, supported by an AMED multi-year grant.

6UI-201
CategoryDrug Candidate (Cancer Vaccine)
Description

A T-cell booster vaccine consisting of PNP carrying NY-ESO-1 long peptide antigen for enhancing engineered T-cell therapies. UI-201 delivers tumor antigen to dendritic cells in lymph nodes to enhance proliferation and tumor-killing activity of TCR-T cells and has completed a Phase 1 trial in combination with NY-ESO-1 TCR-T therapy for advanced soft tissue sarcoma.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Carisma Therapeutics
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-05-21
Description

United Immunity completed acquisition of macrophage-related technology assets from Carisma Therapeutics for the treatment of cancer and liver fibrosis. The assets will be combined with United Immunity's PEG-free P-LNP delivery system to generate in vivo CAR-M and other genetically engineered macrophages.

unitedimmunity.co.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Multi-institution research collaboration for preclinical development of COVID-19 vaccine using Myeloid Targeting Platform. Published results in npj Vaccines (September 2024) demonstrating superior killer T cell induction and infection protection in preclinical animal models.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-07-26
Description

United Immunity entered into a research collaboration agreement with AstraZeneca for the development of next-generation lipid nanoparticles for selective delivery of mRNA and other nucleic acids to immune cells using the Myeloid Targeting Platform. United Immunity provides its proprietary pullulan lipid nanoparticle (P-LNP) technology; AstraZeneca contributes research collaboration resources for joint development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-17
Description

Joint research agreement for next-generation nanoparticle-based T cell-inducing protein vaccine technology targeting SARS-CoV-2. United Immunity provides its nanoparticle vaccine platform; BNC Korea contributes regional development and commercialization resources for the Korean market.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-14
Description

Joint research agreement with Xyphos (US subsidiary of Astellas Pharma) for next-generation cancer immunotherapy using proprietary nanotechnology (nanoAIR program). Collaboration focused on combining United Immunity's nanoparticle delivery technology with Xyphos/Astellas's cell therapy capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-02-04
Description

Exclusive license agreement for T-ignite® technology patents applied by Kyoto University and Mie University. These patents form the foundation of the company's original nanoparticle vaccine technology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-08-31
Description

Material Transfer Agreement (MTA) with Professor Hideho Okada's lab at UCSF for collaborative research on cancer immunotherapy using T-ignite® technology. Research collaboration focused on glioblastoma and other cancer applications.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

United Immunity

Cancer Immunotherapy / Nanoparticle Drug Deliveryunitedimmunity.co.jp

United Immunity is a Tokyo-based Japanese biotech developing the Myeloid Targeting Platform™, a pullulan-based nanoparticle drug delivery technology that selectively targets macrophages and dendritic cells via DC-SIGN receptor binding for cancer immunotherapy and vaccine applications, serving pharmaceutical partners through licensing and co-development agreements.

What United Immunity does

United Immunity Co., Ltd. is a Japanese privately-held biotechnology company founded in November 2017 by Dr. Naozumi Harada and headquartered in Tokyo, with research operations at the Creative Lab for Innovation in Kobe (CLIK). The company develops and commercializes a proprietary drug delivery platform called the Myeloid Targeting Platform™, which consists of two nanoparticle formats built on pullulan polysaccharide chemistry: Pullulan Nanoparticle (PNP) for delivering small molecules, peptides, and proteins; and Pullulan-coated PEG-free Lipid Nanoparticle (P-LNP) for delivering nucleic acids including mRNA, siRNA, and DNA. Both formats selectively bind to the DC-SIGN (CD209) C-type lectin receptor expressed on macrophages and dendritic cells, enabling targeted delivery to tumor-associated macrophages (TAMs) and lymph node myeloid cells while avoiding the anti-PEG antibody issues associated with conventional lipid nanoparticles.

The company's pipeline targets cancer immunotherapy, infectious disease vaccines, and fibrosis applications, with lead candidates including UI-102 (TLR7/8 agonist in PNP for solid tumors, FDA IND cleared March 2026), UI-103 (in vivo CAR-Macrophages using P-LNP), and UI-201 (T-cell booster vaccine for TCR-T cell therapy in synovial sarcoma, Phase 1 completed). United Immunity has exclusively licensed foundational T-ignite® technology from Kyoto University and Mie University, and holds fundamental patents in Japan covering the Myeloid Targeting Platform and P-LNP compositions, with international filings underway.

The company operates a B2B platform licensing and co-development business model, generating revenue through technology licensing (upfront fees, milestones, royalties), research collaboration agreements with pharmaceutical partners (including AstraZeneca and Astellas/Xyphos), and non-dilutive government grants from Japanese agencies such as NEDO and AMED. As a pre-commercial biotech, United Immunity does not yet sell products and depends on partnership income and grant funding to advance its clinical pipeline. The company is supported by venture investors including Saisei Ventures, UTEC, Axil Capital, TOHO Holdings, and Rico Biomedical Startup Fund, and secured venture debt from Aozora Corporate Investment in March 2024.

United Immunity firmographics

Firmographics
Name
United Immunity
Legal name
United Immunity Co., Ltd.
Website
https://unitedimmunity.co.jp
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
United Immunity is a Tokyo-based Japanese biotech developing the Myeloid Targeting Platform™, a pullulan-based nanoparticle drug delivery technology that selectively targets macrophages and dendritic cells via DC-SIGN receptor binding for cancer immunotherapy and vaccine applications, serving pharmaceutical partners through licensing and co-development agreements.
Ownership category
akta.pro rank

United Immunity industry classification

Industry
Product category
Cancer Immunotherapy / Nanoparticle Drug Delivery
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Cancer immunotherapy
  • Nanoparticle drug delivery
  • Myeloid cell targeting
  • Lipid nanoparticle platform
  • Immuno-oncology platform

Where United Immunity is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

United Immunity business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: United Immunity licenses its Myeloid Targeting Platform technology, PNP, and P-LNP to pharmaceutical partners for use in their drug development programs. Licensing revenue derives from upfront payments, milestone payments, and royalties on approved products.
  2. Co-Development and Research Collaborations: The company enters joint research and co-development agreements with pharma companies (e.g., AstraZeneca, Astellas/Xyphos) where collaborative R&D generates funding through research fees, milestone payments, and future commercial royalties.
  3. Government Grants: United Immunity receives non-dilutive funding from Japanese government agencies including NEDO (Deep Tech/Startup support grant) and AMED (Strengthening Program for Pharmaceutical Startup Ecosystem; CiCLE grants), supporting preclinical and clinical development of pipeline programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

United Immunity product offering

Product offering

Core offering

United Immunity develops and licenses the Myeloid Targeting Platform™, a proprietary nanoparticle drug delivery system comprising Pullulan Nanoparticle (PNP) and PEG-free Pullulan-coated Lipid Nanoparticle (P-LNP) that selectively deliver therapeutic payloads (small molecules, peptides, proteins, mRNA, siRNA, DNA) to macrophages and dendritic cells via DC-SIGN receptor binding. The company applies this platform to build an internal pipeline of immuno-oncology drug candidates (UI-102, UI-103, UI-201) and offers the technology to pharmaceutical partners through licensing, co-development, and research collaborations.

Product overview

United Immunity is a biotech company developing a proprietary Myeloid Targeting Platform™ consisting of two nanoparticle delivery systems: Pullulan Nanoparticle (PNP) for small molecules, peptides, and proteins, and Pullulan Lipid Nanoparticle (P-LNP) for nucleic acids (mRNA, siRNA, DNA). Both technologies selectively target macrophages and dendritic cells via DC-SIGN receptor binding. The company applies this platform to develop pipeline candidates including UI-102 (TLR7/8 agonist in PNP for solid tumors), UI-103 (in vivo CAR-Macrophages using P-LNP), and UI-201 (T-cell booster vaccine for TCR-T therapy). The platform enables drug delivery to tumor-associated macrophages and dendritic cells for cancer immunotherapy and vaccine applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Myeloid Targeting Platform™: Proprietary drug delivery platform using pullulan nanoparticles (PNP) and pullulan-coated lipid nanoparticles (P-LNP) for selective targeting of macrophages and dendritic cells via DC-SIGN receptor.

Products and services

  • Myeloid Targeting Platform™ A proprietary nanoparticle-based drug delivery platform technology that enables selective delivery of therapeutic agents to disease- and vaccination-associated macrophages and dendritic cells through specific binding of pullulan polysaccharide to the DC-SIGN receptor. The platform comprises two nanoparticle formats (PNP and P-LNP) supporting delivery of small molecules, peptides, proteins, and nucleic acids, and is licensed to and co-developed with pharmaceutical partners for cancer immunotherapy, infectious disease, autoimmune disease, fibrosis, and metabolic disease applications.
  • Pullulan Nanoparticle (PNP) A nanoparticle consisting of cholesterol-modified pullulan polysaccharide formed by self-assembly through hydrophobic interaction. PNP encapsulates hydrophobic small molecules, peptides, and proteins and is administered via intravenous, subcutaneous, or intramuscular injection. It specifically targets DC-SIGN-expressing macrophages and dendritic cells for drug delivery and is non-antigenic, supporting multiple dosing.
  • Pullulan Lipid Nanoparticle (P-LNP) A next-generation PEG-free lipid nanoparticle technology coated with pullulan polysaccharide, designed for delivery of mRNA, siRNA, and DNA to disease- and vaccination-associated myeloid cells. P-LNP avoids anti-PEG antibody-associated adverse effects and provides selectivity toward macrophages and dendritic cells via DC-SIGN binding.
  • UI-102 A PNP formulation encapsulating a TLR7/8 agonist for systemic injection targeting M2-like tumor-associated macrophages. UI-102 selectively accumulates in tumors where it repolarizes immunosuppressive M2-like TAMs into immunostimulatory M1-like TAMs, converting 'cold' tumors into 'hot' tumors. It is in Phase 1/2 development for solid tumors as monotherapy or in combination with checkpoint inhibitors, and received FDA IND clearance in March 2026.
  • UI-103 (In Vivo CAR-Macrophages) An in vivo CAR-macrophage therapy program using P-LNP to deliver CAR mRNA directly to tumor-associated macrophages. The approach aims to generate CAR-M cells within the patient's body for off-the-shelf treatment of solid tumors with lower manufacturing costs and potential for repeat dosing, supported by an AMED multi-year grant.
  • UI-201 A T-cell booster vaccine consisting of PNP carrying NY-ESO-1 long peptide antigen for enhancing engineered T-cell therapies. UI-201 delivers tumor antigen to dendritic cells in lymph nodes to enhance proliferation and tumor-killing activity of TCR-T cells and has completed a Phase 1 trial in combination with NY-ESO-1 TCR-T therapy for advanced soft tissue sarcoma.

Quantifiable outcome

  • UI-102 showed strong single-agent anti-tumor activity in multiple preclinical cold tumor models and clear synergy with checkpoint inhibitors in treatment-resistant tumor models
  • +2 more outcomes

Companies that use United Immunity

Customer profile

Segments3 records

Ideal customer profiles2 records

United Immunity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

United Immunity partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, core and minor.

  • Carisma TherapeuticsmajorTechnology or Integration · 21 May 2026United Immunity completed acquisition of macrophage-related technology assets from Carisma Therapeutics for the treatment of cancer and liver fibrosis. The assets will be combined with United Immunity's PEG-free P-LNP delivery system to generate in vivo CAR-M and other genetically engineered macrophages.
  • University of Tokyo, Kyoto University, Nagasaki University, Aichi Cancer CentercoreStrategic or Co-development Partner · 1 October 2024Multi-institution research collaboration for preclinical development of COVID-19 vaccine using Myeloid Targeting Platform. Published results in npj Vaccines (September 2024) demonstrating superior killer T cell induction and infection protection in preclinical animal models.
  • AstraZenecamajorStrategic or Co-development Partner · 26 July 2024United Immunity entered into a research collaboration agreement with AstraZeneca for the development of next-generation lipid nanoparticles for selective delivery of mRNA and other nucleic acids to immune cells using the Myeloid Targeting Platform. United Immunity provides its proprietary pullulan lipid nanoparticle (P-LNP) technology; AstraZeneca contributes research collaboration resources for joint development.
  • BNC KoreaminorStrategic or Co-development Partner · 17 February 2022Joint research agreement for next-generation nanoparticle-based T cell-inducing protein vaccine technology targeting SARS-CoV-2. United Immunity provides its nanoparticle vaccine platform; BNC Korea contributes regional development and commercialization resources for the Korean market.
  • Xyphos/Astellas PharmamajorStrategic or Co-development Partner · 14 January 2021Joint research agreement with Xyphos (US subsidiary of Astellas Pharma) for next-generation cancer immunotherapy using proprietary nanotechnology (nanoAIR program). Collaboration focused on combining United Immunity's nanoparticle delivery technology with Xyphos/Astellas's cell therapy capabilities.
  • Kyoto University and Mie UniversitycoreTechnology or Integration · 4 February 2020Exclusive license agreement for T-ignite® technology patents applied by Kyoto University and Mie University. These patents form the foundation of the company's original nanoparticle vaccine technology.
  • UCSF (University of California, San Francisco)minorStrategic or Co-development Partner · 31 August 2019Material Transfer Agreement (MTA) with Professor Hideho Okada's lab at UCSF for collaborative research on cancer immunotherapy using T-ignite® technology. Research collaboration focused on glioblastoma and other cancer applications.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

United Immunity competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

United Immunity social profiles

Digital presence

United Immunity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

United Immunity leadership team

Management profile

Number of profiles

Profiles6 records

United Immunity funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

United Immunity M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about United Immunity

What does United Immunity do?

United Immunity develops and licenses the Myeloid Targeting Platform™, a proprietary nanoparticle drug delivery system comprising Pullulan Nanoparticle (PNP) and PEG-free Pullulan-coated Lipid Nanoparticle (P-LNP) that selectively deliver therapeutic payloads (small molecules, peptides, proteins, mRNA, siRNA, DNA) to macrophages and dendritic cells via DC-SIGN receptor binding. The company applies this platform to build an internal pipeline of immuno-oncology drug candidates (UI-102, UI-103, UI-201) and offers the technology to pharmaceutical partners through licensing, co-development, and research collaborations.

Is United Immunity a public or private company?

United Immunity is a private company. It is classified as venture growth investor backed and is currently operating.

When was United Immunity founded?

United Immunity was founded in 2017. It employs 11 to 50 people.

Where is United Immunity based?

United Immunity is headquartered in Tokyo, Japan, in the Asia region.

How does United Immunity make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are co-Development and Research Collaborations and government Grants.

Does United Immunity have an API?

No public API is recorded for United Immunity.

What industry is United Immunity in?

United Immunity's product category is Cancer Immunotherapy / Nanoparticle Drug Delivery. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals